Table 2.
Summary of the phenotype of DT40 and TK6 mutants analyzed by this study
| Genotype | The name of cell line | The method of conditional inactivation | Cell growth (doubling time) |
|---|---|---|---|
| Wild-type | TK6 | Proliferating (14 h) | |
| MRE11loxP/loxP | TK6 | Tamoxifen | Lethal |
| MRE11WT/WT | TK6 | Proliferating (14 h) | |
| MRE111oxP/WT | TK6 | Tamoxifen | Proliferating (14 h) |
| MRE111oxP/H129N | TK6 | Tamoxifen | Lethal |
| CtIPWT/WT | TK6 | Proliferating (14 h) | |
| CtIPND/ND (ND: N181A/R185A) | TK6 | Proliferating (14 h) | |
| CtIpmAID/mAID | TK6 | Auxin | Lethal |
| RAD54−/− | TK6 | Proliferating (15.5 h) | |
| MRE11−/− | ATLD2 | Proliferating | |
| NBS1ΔN† | GM07166 | Proliferating | |
| MRE11−/− reconstituted with a MRE11 transgene | ATLD2-MRE11 | Proliferating | |
| NBS1ΔN reconstituted with a NBS1 transgene† | NBS1ΔN-NBS1 | Proliferating | |
| Wild-type | DT40 | Proliferating (8 h) | |
| EXO1−/− | DT40 | Proliferating (8 h) | |
| DNA2−/K623E | DT40 | Doxycycline | Lethal |
| DNA2−/D245A/EXO1−/− | DT40 | Doxycycline | Lethal |
| CtIP−/−/− | DT40 | Doxycycline | Lethal |
| CtIP−/−/ND | DT40 | Doxycycline | Proliferating |
| MRE11−/H129N | DT40 | Proliferating (21 h) |
†
The genotype is not clear. The cells express an N-terminal truncated Nbs1 protein.